Haematology

Chemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)

Chemotherapy-free regimens for pediatric acute promyelocytic leukemia (APL) demonstrate superior efficacy and reduced toxicity compared to traditional chemotherapy.

Personalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches

EHA 2026 discussions focused on individualized hemophilia care, moving beyond standard prophylaxis to tailored treatment strategies based on patient-specific factors.

Macrophages: Dual Role in Haematological Malignancies Explored

Macrophages exhibit a dual role in haematological malignancies, acting as both tumour suppressors and promoters, influencing disease progression and therapeutic responses.

Molecular Hematology: From Gene Profiles to Therapy Profiles at EHA 2026

EHA 2026 will review a quarter-century of molecular hematology, focusing on the integration of genomic data into targeted therapeutic strategies.

ITP Management: Bridging Clinician and Patient Perspectives

Effective immune thrombocytopenia (ITP) management requires aligning clinician treatment goals with patient quality of life priorities.

CLL: Aligning Patient Priorities with Targeted Therapy at EHA 2026

Strategies for initiating and sequencing targeted therapy in CLL must align with patient priorities and evidence for long-term benefit.

Myelofibrosis Management: Cytopenia Guides Treatment at EHA 2026

EHA 2026 discussions on cytopenic myelofibrosis focused on risk stratification and treatment selection, emphasizing ruxolitinib and pacritinib.

CAR T: Speed and Reliability Critical for Patient Outcomes

CAR T-cell therapy for glioblastoma multiforme (GBM) requires rapid, reliable delivery to improve patient outcomes, addressing current translational limitations.

DLBCL Management: Bispecific Antibodies as Emerging Therapeutic Option

Diffuse Large B-Cell Lymphoma (DLBCL) management faces challenges in relapsed/refractory settings. Bispecific antibodies offer a novel therapeutic approach.

CAR T-Cell Therapy Guidelines Evolve for Lymphoma, Myeloma at EHA 2026

EHA 2026 discussions highlight evolving CAR T-cell therapy guidelines for lymphoma and multiple myeloma, focusing on patient selection and sequencing.